6.40 +0.35 (5.79%)
After hours: 4:57PM EDT
|Bid||6.05 x 700|
|Ask||6.25 x 500|
|Day's Range||5.80 - 6.19|
|52 Week Range||1.50 - 10.65|
|PE Ratio (TTM)||46.54|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sorrento Therapeutics (SRNE) is a clinical-stage biotechnology company. Its research programs are targeted at autoimmune, inflammatory, and neurodegenerative diseases and pain indications. Essentially, Sorrento Therapeutics is an antibody-centric company and leverages its G-MAB library to generate product candidates.
Sorrento Therapeutics (SRNE) aims to use its antibodies along with its proprietary targeted delivery modalities to generate therapies for cancer. Additionally, Sorrento Therapeutics has acquired late-stage biosimilar antibodies based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics expects to submit an Investigational New Drug Application (or IND) for at least one of these two programs with the FDA in 2018.
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is one of the biggest movers in the biotechnology space as we head into the latter half of this week on some news related to one of the company’s lead development programs. Here’s what happened and what it means for the company and its shareholders. The news relates to a drug […] The post Here’s Why Sorrento Is Running Today appeared first on Market Exclusive.
Sorrento Therapeutics Inc said on Wednesday the U.S. Food and Drug Administration has approved ZTlido, its non-opioid painkiller patch for nerve pain related to shingles, which it plans to launch later this year. ZTlido, which Sorrento added as part of its 2016 acquisition of majority stake in privately-held SCILEX Pharmaceuticals Inc, was approved for postherpetic neuralgia (PHN), a common complication of shingles that manifests as a burning pain.
The U.S. Food And Drug Administration on Wednesday approved Sorrento Therapeutics Inc's ZTlido, a stick-on patch to treat nerve pain due to shingles. Sorrento, which acquired Ztlido when it bought a majority ...
When Sorrento Therapeutics Inc’s (NASDAQ:SRNE) announced its latest earnings (30 September 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks I usedRead More...
Jan 29 (Reuters) - Sorrento Therapeutics Inc: * CHINA ONCOLOGY FOCUS LIMITED RECEIVES APPROVAL BY CHINESE AUTHORITIES TO BEGIN CLINICAL TRIALS IN THREE SEPARATE CANCER INDICATIONS USING SORRENTO’S ANTI-PD-L1 ...
Biotech M&A got another boost this morning as French drugmaker Sanofi SA (ADR) (NYSE:SNY) said it will buy Belgian biotech firm ABLYNX N.V. (OTCMKTS:ABLYF) for about $4.8 billion, just a week after inking a deal to buy hemophilia specialist Bioverativ Inc. (NASDAQ:BIVV) for $11.6 billion. Ablynx rejected a 2.6 billion euro offer from Denmark’s Novo Nordisk A/S (ADR) (NYSE:NVO), according to The Wall Street Journal. The Danish firm does not intend to make a revised offer for Ablynx, which is developing a prized experimental drug for a rare blood disorder, the newspaper reported.
Categories: Yahoo FinanceGet free summary analysis Sorrento Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 121.91 million, Net Earnings of USD 33.96 million. Gross margins widened from 76.37% to 97.99% compared to the same period last year, operating (EBITDA) margins now 78.28% from -608.29%. Change in operating ... Read more (Read more...)